



INVESTIGATION OF DEEP B-CELL DEPLETION FOR IMMUNE RESET: TRIAL DESIGN CONSIDERATIONS

HEALTHY VOLUNTEERS VS PATIENTS IN EARLY-PHASE B-CELL THERAPY STUDIES

For *in vivo* CAR-T and T-cell engagers, one of the earliest and most important study design decisions is whether to begin in healthy volunteers or in patients.

SAFETY CONSIDERATIONS

Start in Healthy Volunteers

To generate human clinical pharmacology data and characterize B-cell depletion and recovery kinetics.

Suitable for investigational products with low risk of cytokine release syndrome (CRS).

OR

Start in Patients

When premedication to reduce the potential incidence or severity of CRS is a consideration, and when early efficacy is needed.

Starting doses will be subtherapeutic, with limited potential for early Pharmacodynamics (PD) and efficacy readouts.

Healthy Volunteers vs Patients



Healthy Volunteers (HV)

Speed and Data Clarity

- Pros**
- Faster recruitment
 - Access to large volunteer databases
 - Cleaner Pharmacokinetics(PK)/ Pharmacodynamics (PD) signals
 - Earlier dose de-risking
 - Helps identify biologically active dose ranges
 - May reduce exposure of rare patients to subtherapeutic doses
- Cons**
- Vaccination restrictions
 - Limited dosing duration in some settings



Patients

Earlier Biological and Clinical Insight

- Pros**
- Earlier efficacy signal
 - Disease-relevant biological context
 - Tissue-level validation
 - Supports basket disease indication studies
 - Disease indication-specific data for B-cell depletion kinetics
- Cons**
- Disease indication recruitment rate is typically lower than for HVs
 - Prior treatment failure often required
 - Heterogeneous outcome measures
 - Greater biological variability
 - More operational complexity and potentially longer duration of trial

Best used when: dose-depletion behavior is the key question

Best used when: biological relevance or early efficacy is the key question

Data-Led Pivot from HVs to Patients

HVs

Example pivot criterion:
Peripheral blood B-cell suppression sustained for < 2 months
Pivot should be data-led, not date-led

Patients



Prepare ethics and patient-site readiness in advance



Plan governance before the pivot is needed

Operational Enablers

Rapid Biomarker Turnaround

TBNK flow cytometry on live whole blood should be processed rapidly—ideally within 24 hours, no later than 72 hours—to inform dose escalation, safety review, depletion depth, nadir timing, and early recovery kinetics.

Safety Monitoring Priorities

Treat CRS as an early monitoring priority. Watch for fever, malaise, shortness of breath, cardiovascular changes, subtle ICANS-like neurologic signs, and viral reactivation risk.

Adaptive Study Execution

Successful studies depend on flexible protocols, rapid safety review, pre-planned cohort transitions, and close coordination between the site, CRO, sponsor, and lab.

Examples of patient cohorts/basket indications

Systemic Lupus Erythematosus (SLE)

Rheumatoid Arthritis (RA)

IgA nephropathy (IgAN)

Idiopathic inflammatory myopathies

Scleroderma

Sponsor takeaway: Programs move most efficiently when recruitment strategy, safety monitoring, biomarker logistics, and pivot planning are aligned from the outset.

The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com